MSB 10.4% $1.49 mesoblast limited

Australian newspaper article, page-56

  1. 3,960 Posts.
    lightbulb Created with Sketch. 1357
    He is still suggesting that a 6 month review is possible so is not over promising. This leaves the possible acition date open. FDA may still set a 2 month review. Not expected but not ruled out either.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.